Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04976361
Other study ID # VD befor and after PRP
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2019
Est. completion date May 1, 2021

Study information

Verified date July 2021
Source Minia University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study, OCTA is used to study the vascular changes following PRP in patients with PDR; regarding vessels density at 1 month and 6 months follow up period and measure superficial, deep, and outer retina for fovea, para-fovea and whole image.


Description:

The global prevalence of diabetes mellitus in 2019 is estimated to be 9.3% (463 million people).1 Diabetic retinopathy (DR) is microangiopathy characterized by capillary non- perfusion, microaneurysms (MAs), and retinal ischemia. 2It may cause many complications, such as diabetic macular edema (DME) and diabetic macular ischemia (DMI).3 Capillary ischemia decreases the nutrition of the retina and causes hypoxia which results in increased level of vascular endothelial growth factor (VEGF), which promotes angiogenic responses causing both neovascularization (proliferative diabetic retinopathy, PDR) and vascular permeability (macular edema). Panretinal photocoagulation (PRP) by argon or diode laser is the standard treatment for proliferative diabetic retinopathy. It improves oxygenation to the ischemic retina. Destruction of the highly active photoreceptor cells is the suggested mechanism of action for PRP. Subsequently, production of vascular endothelial growth factor (VEGF), the key player in neovascularization process, is reduced leading to regression of new vessels.5 PDR eyes have an overall lower blood flow than normal or non-PDR eyes, parallel to the higher level of retinal ischemia and disease severity. With regression of these neovascular and shunt vessels following PRP, normalization of flow in the macula may reverse the ischemia and decrease the stimulus for new blood vessel formation. Closure of intraretinal microvascular abnormalities and neovascularization would theoretically increase overall resistance to flow and, combined with the constriction of the large vessel in response to increased oxygen in the inner retina, collectively decrease the overall blood flow.6 While most previous studies have explored the large vessel effects of PRP, the development of ocular coherence tomography angiography (OCTA) allowed the study of microvascular retinal changes in a detailed manner. It is a non-invasive modality that allows vascular mapping with high speed and quality and promotes visualization of vascular system in different retinal and choroidal levels. Several investigations have demonstrated the competence of OCTA in the quantification of microvascular density, choroidal flow area, and foveal avascular zone (FAZ) area in diabetic patients.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date May 1, 2021
Est. primary completion date April 1, 2021
Accepts healthy volunteers No
Gender All
Age group 40 Years to 60 Years
Eligibility Inclusion Criteria: - patients with type 2 diabetes with PDR - treatment-naive PDR diabetic patients diagnosed clinically and by the presence of neovascularization on optic disc (NVDs) or elsewhere (NVEs) on fluorescein angiography. Exclusion Criteria: - Patients with significant media opacity decreasing image quality -. Eyes with significant macular edema - patients with glaucoma, uveitis, previous intraocular surgery, and history of previous treatment for diabetic retinopathy including anti-VEGF and laser - patients with low signal strength index (SSI; <50) - presence of 1 or more blink artifacts - poor fixation leading to motion artifacts.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
PRP was done using visulas green laser machine (Carl Zeiss Meditec AG Geoschwitzer Str. 51-52,07745 jena, Germany)
PRP was done using visulas green laser machine (Carl Zeiss Meditec AG Geoschwitzer Str. 51-52,07745 jena, Germany)

Locations

Country Name City State
Egypt Minia University Hospital Minya

Sponsors (1)

Lead Sponsor Collaborator
Minia University

Country where clinical trial is conducted

Egypt, 

References & Publications (8)

Adhi M, Brewer E, Waheed NK, Duker JS. Analysis of morphological features and vascular layers of choroid in diabetic retinopathy using spectral-domain optical coherence tomography. JAMA Ophthalmol. 2013 Oct;131(10):1267-74. doi: 10.1001/jamaophthalmol.2013.4321. — View Citation

Cuypers MH, Kasanardjo JS, Polak BC. Retinal blood flow changes in diabetic retinopathy measured with the Heidelberg scanning laser Doppler flowmeter. Graefes Arch Clin Exp Ophthalmol. 2000 Dec;238(12):935-41. — View Citation

Ghassemi F, Fadakar K, Bazvand F, Mirshahi R, Mohebbi M, Sabour S. The Quantitative Measurements of Vascular Density and Flow Areas of Macula Using Optical Coherence Tomography Angiography in Normal Volunteers. Ophthalmic Surg Lasers Imaging Retina. 2017 Jun 1;48(6):478-486. doi: 10.3928/23258160-20170601-06. — View Citation

Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015 Sep 30;2:17. doi: 10.1186/s40662-015-0026-2. eCollection 2015. Review. — View Citation

Miwa Y, Murakami T, Suzuma K, Uji A, Yoshitake S, Fujimoto M, Yoshitake T, Tamura Y, Yoshimura N. Relationship between Functional and Structural Changes in Diabetic Vessels in Optical Coherence Tomography Angiography. Sci Rep. 2016 Jun 28;6:29064. doi: 10.1038/srep29064. — View Citation

Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985 Dec;103(12):1796-806. — View Citation

Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R; IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019 Nov;157:107843. doi: 10.1016/j.diabres.2019.107843. Epub 2019 Sep 10. — View Citation

Savage HI, Hendrix JW, Peterson DC, Young H, Wilkinson CP. Differences in pulsatile ocular blood flow among three classifications of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4504-9. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Measurement of vessel density Measurement of vessel density at superficial, deep, and outer retina at base line, after 1 month, and after 6 months. 6 months
Primary Measurement of retinal thickness central retinal thickness at base line, after 1 month, and after 6 months. 6 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05160441 - Comparing Platelet Rich Plasma and Corticosteroid for Military & Civilian Patients With Glenohumeral Osteoarthritis Phase 3
Enrolling by invitation NCT05944757 - Compare of PRP Autologous Serum and Autologous Serum by Intrastromal Injection in Different Eye Disease Conditions N/A
Not yet recruiting NCT03633266 - Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy N/A
Recruiting NCT03830775 - A Prospective Randomized Double Blinded Controlled Trial of Non-Operative Management of TFCC Injuries N/A
Recruiting NCT04811287 - PRP as Adjuvant Treatment to CTR for Severe CTS Tunnel Syndrome N/A
Recruiting NCT04586361 - Prospective Analysis of Introperative RegenLab PRP and Hyaluronic Acid in Patients With Knee ACL Tear Phase 4
Completed NCT05827484 - The Effect of Combined Use of Anti-fibrotic Agent With Platelet Rich Plasma on Skeletal Muscle Healing After Acute Injuries Phase 4
Recruiting NCT04765930 - Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in Melasma N/A
Terminated NCT03937765 - The Effect of Platelet Rich Plasma on Pain at Skin Graft Donor Sites N/A
Recruiting NCT05241964 - Platelet-rich Plasma(PRP) Injection in ED N/A
Recruiting NCT05279560 - Ovarian PRP (Platelet Rich Plasma) Injection for Follicular Activation N/A
Not yet recruiting NCT06298110 - The Effect of PRP on Wound Healing in High Risk Patients Undergoing Abdominal Hysterectomy Phase 2/Phase 3
Recruiting NCT06028009 - PRP Injections for Genitourinary Syndrome of Menopause N/A
Recruiting NCT05412381 - PRP in ACLR to Prevent PTOA Phase 4
Active, not recruiting NCT04556825 - Arthroscopic Treatment Combined With PRP Injection for Refractory Elbow Epicondylitis N/A
Recruiting NCT03987256 - ECRB Tendinopathy: Needling ± PRP After Failure of Rehabilitation N/A
Completed NCT04320498 - Short Term Results of Platelet-rich Plasma in the Treatment of Chronic Anal Fissure Phase 4
Completed NCT04640662 - The Effects of Platelet-Rich Plasma Versus Prolotherapy On Rotator Cuff Tendinopathy: A Randomized Controlled Trial. Phase 1
Completed NCT03371888 - The Platelet-Rich Plasma in the Therapy of Temporomandibular Disorders Phase 2/Phase 3
Recruiting NCT04519047 - IA Injection of Rejoint Gel and PRP in Patients With Unilateral Knee OA Phase 1